L. Zhang
University of Groningen · 40 works · 784 citations · h-index 10
Top works
- Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
- LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis
- The impact of sharing results of a randomized breast cancer clinical trial with study participants
- Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC
- Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial
- Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC)
- LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
- Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
- Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
- Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
- 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)
- PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
- P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS
- Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy
- The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
- 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
- Mendelian randomization study showed no causality between metformin use and lung cancer risk
- Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
- 445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK +) non-small cell lung cancer (NSCLC) previously treated with crizotinib
- Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs